Bristol Myers Squibb (CELG-RI) Inventory (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Inventory for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Inventory changed 0.0% year-over-year to $2.7 billion in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 5.2% from the prior year.
• Inventory was $2.7 billion for Q2 2026 at Bristol Myers Squibb, down from $2.8 billion in the prior quarter.
• Over five years, Inventory peaked at $3.3 billion in Q3 2024 and troughed at $2.1 billion in Q3 2022.
• A 5-year average of $2.6 billion and a median of $2.7 billion in 2023 frame the typical range for Inventory.
• Across the five-year window, Inventory surged 36.78% in 2024 and slipped 17.23% in 2025, its largest moves.
• Over 5 years, Inventory stood at $2.3 billion in 2022, then increased by 13.81% to $2.7 billion in 2023, then retreated by 3.94% to $2.6 billion in 2024, then grew by 5.2% to $2.7 billion in 2025, then climbed by 1.75% to $2.7 billion in 2026.
• The last three Inventory figures came in at $2.7 billion (Q2 2026), $2.8 billion (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.